Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Secures German ISO Certification

NEW YORK (GenomeWeb News) – Proteome Sciences said today that it has received ISO certification in Germany for its contract research lab in Frankfurt.

The company, which offers protein biomarker and isobaric mass tagging contract services, received ISO 9001:2008 certification from the German Society for Certification of Management Systems.

The certification covers the company's biomarker activities, rapid mass spectrometry-based assay development for protein and peptide drugs, chemical and peptide synthesis, and isobaric tagging development and production.

Proteome Sciences CEO Christopher Pearce said in a statement that the certification "allows us to more comprehensively exploit the fast-growing field of protein biomarker qualification and mass spectrometry assays through the provision of ISO certified biomarker services for our customers."

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.